Effects of troponin-I extraction with vanadate and of the calcium sensitizer EMD 53998 on the rate of force generation in skinned cardiac muscle.
The rate of tension development following release of ATP from caged-ATP in the presence of calcium was studied in skinned cardiac fibres from swine. A low-force rigor state was obtained by using butanedione monoxime (BDM) during the induction of rigor. BDM was washed out and following release of ATP in the presence of Ca2+ (pCa 4.3), the muscles contracted with an apparent rate of about 2 s-1 at 22 degrees C. After treatment with 10 mM vanadate to extract troponins I and C the fibres contracted independently of calcium. The rate of contraction upon release of ATP was slower than prior to extraction and was independent of [Ca2+]. Since treatment with vanadate has been shown to extract about 90% of troponin-I the results suggest that the muscles under these conditions are partially activated by removal of an inhibition of cross-bridge interaction by troponin I. A partial recovery of force was obtained by prolonged incubation in DTT containing solutions possibly reflecting reconstitution with troponin I still present in the fibre bundle. Treatment with a solution containing whole troponin caused almost complete recovery of calcium sensitivity and rate of force development. The calcium sensitizer EMD 53998 increased rates of contraction in a dose dependent manner, suggesting that this compound increases force and calcium sensitivity by increasing the cross-bridge attachment rates.
Arner
A
A
Department of Physiology and Biophysics, Lund University, Sweden.
Strauss
J D
JD
Svensson
C
C
Rüegg
J C
JC
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000378:metabolism; D000818:Animals; D002118:Calcium / Q000502:physiology*; D002316:Cardiotonic Agents / Q000494:pharmacology*; D066298:In Vitro Techniques; D007700:Kinetics; D018485:Muscle Fibers, Skeletal / Q000187:drug effects / Q000502:physiology; D009132:Muscles / Q000187:drug effects / Q000502:physiology*; D009200:Myocardial Contraction / Q000187:drug effects / Q000502:physiology*; D009206:Myocardium / Q000378:metabolism; D010782:Photolysis; D011804:Quinolines / Q000494:pharmacology*; D013552:Swine; D013829:Thiadiazines / Q000494:pharmacology*; D013997:Time Factors; D014336:Troponin / Q000302:isolation & purification / Q000502:physiology*; D019210:Troponin I; D014638:Vanadates / Q000494:pharmacology*
D002316:Cardiotonic Agents; D011804:Quinolines; D013829:Thiadiazines; D014336:Troponin; D019210:Troponin I; C070609:EMD 53998; D014638:Vanadates; C029273:P(3)-1-(2-nitro)phenylethyladenosine 5'-triphosphate; D000255:Adenosine Triphosphate; D002118:Calcium